FK 866 hydrochloride

Description: Potent and non-competitive NAMPT inhibitor; induces apoptosis and autophagy
Chemical Name: 2-(E)-N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews (1)
Literature (1)

Biological Activity for FK 866 hydrochloride

FK 866 hydrochloride is a non-competitive and potent inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, PBEF1) (Ki = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC50 ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by etoposide (Cat. No. 1226) and cisplatin (Cat. No. 2251).

Technical Data for FK 866 hydrochloride

M. Wt 427.97
Formula C24H29N3O2.HCl
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 2727965-45-7
PubChem ID 78243733
InChI Key MULSIBUGDPOSHV-CALJPSDSSA-N
Smiles O=C(C2=CC=CC=C2)N1CCC(CCCCNC(/C=C/C3=CN=CC=C3)=O)CC1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for FK 866 hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for FK 866 hydrochloride

References are publications that support the biological activity of the product.

Travelli et al (2011) Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etop. or cisp. in neuroblastoma cells. J.Pharmacol.Exp.Ther. 338 829 PMID: 21685314

Hasmann et al (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 7436 PMID: 14612543

Galli et al (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem 3 771 PMID: 18247435

View Related Products by Product Action

View all NAMPT Inhibitors

Keywords: FK 866 hydrochloride, FK 866 hydrochloride supplier, FK866, hydrochloride, Nicotinamide, phosphoribosyltransferase, NMPRTase, inhibitors, inhibits, autophagy, apoptosis, NAD, NAMPT, visfatin, PBEF, Apoptosis, Inducers, Autophagy, 4808, Tocris Bioscience

2 Citations for FK 866 hydrochloride

Citations are publications that use Tocris products. Selected citations for FK 866 hydrochloride include:

Ian A et al (2021) Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation. Cell Metab 33 94-109.e8 PMID: 33159852

Singh et al (2018) Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of MTX through Enhanced Depletion of Intracellular ATP. J Pharmacol Exp Ther 365 96 PMID: 29420256


Reviews for FK 866 hydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used FK 866 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


NAD inhibitor.
By Kishor Pant on 04/07/2022
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: Cancer and liver cell lines

FK866 Inhibits NAD+ production and NAMPT activity in cancer cells.

Inhibition of NAD in cancer cells requires 3-4 days of treatment

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.